全文获取类型
收费全文 | 175573篇 |
免费 | 11807篇 |
国内免费 | 700篇 |
专业分类
耳鼻咽喉 | 2498篇 |
儿科学 | 4870篇 |
妇产科学 | 3445篇 |
基础医学 | 22499篇 |
口腔科学 | 3542篇 |
临床医学 | 17334篇 |
内科学 | 37180篇 |
皮肤病学 | 2801篇 |
神经病学 | 17711篇 |
特种医学 | 6189篇 |
外国民族医学 | 13篇 |
外科学 | 26356篇 |
综合类 | 2288篇 |
现状与发展 | 3篇 |
一般理论 | 201篇 |
预防医学 | 13085篇 |
眼科学 | 4764篇 |
药学 | 11471篇 |
中国医学 | 198篇 |
肿瘤学 | 11632篇 |
出版年
2023年 | 642篇 |
2022年 | 482篇 |
2021年 | 2605篇 |
2020年 | 1763篇 |
2019年 | 2891篇 |
2018年 | 3401篇 |
2017年 | 2455篇 |
2016年 | 2863篇 |
2015年 | 3458篇 |
2014年 | 5117篇 |
2013年 | 7889篇 |
2012年 | 11405篇 |
2011年 | 12273篇 |
2010年 | 6848篇 |
2009年 | 6308篇 |
2008年 | 11550篇 |
2007年 | 12318篇 |
2006年 | 11808篇 |
2005年 | 12174篇 |
2004年 | 11562篇 |
2003年 | 11042篇 |
2002年 | 10617篇 |
2001年 | 1462篇 |
2000年 | 1067篇 |
1999年 | 1448篇 |
1998年 | 1919篇 |
1997年 | 1633篇 |
1996年 | 1332篇 |
1995年 | 1531篇 |
1994年 | 1369篇 |
1993年 | 1303篇 |
1992年 | 1005篇 |
1991年 | 959篇 |
1990年 | 826篇 |
1989年 | 814篇 |
1988年 | 830篇 |
1987年 | 714篇 |
1986年 | 831篇 |
1985年 | 907篇 |
1984年 | 1191篇 |
1983年 | 1142篇 |
1982年 | 1601篇 |
1981年 | 1479篇 |
1980年 | 1365篇 |
1979年 | 751篇 |
1978年 | 883篇 |
1977年 | 770篇 |
1976年 | 680篇 |
1975年 | 554篇 |
1974年 | 579篇 |
排序方式: 共有10000条查询结果,搜索用时 203 毫秒
61.
Frederick R. Taylor MD FAAN FAHS Wade Cooper DO Robert G. Kaniecki MD 《Headache》2020,60(8):1857-1867
62.
63.
Higuchi Takashi Sugisawa Norihiko Yamamoto Jun Oshiro Hiromichi Han Qinghong Yamamoto Norio Hayashi Katsuhiro Kimura Hiroaki Miwa Shinji Igarashi Kentaro Tan Yuying Kuchipudi Shreya Bouvet Michael Singh Shree Ram Tsuchiya Hiroyuki Hoffman Robert M. 《Cancer chemotherapy and pharmacology》2020,85(2):285-291
Cancer Chemotherapy and Pharmacology - Cancers are methionine (MET) and methylation addicted, causing them to be highly sensitive to MET restriction. The present study determined the efficacy of... 相似文献
64.
65.
Nicholas S. Phillips Yin Ting Cheung John O. Glass Matthew A. Scoggins Wei Liu Robert J. Ogg Daniel A. Mulrooney Ching‐Hon Pui Leslie L. Robison Wilburn E. Reddick Melissa M. Hudson Kevin R. Krull 《Pediatric blood & cancer》2020,67(3)
Survivors of childhood acute lymphoblastic leukemia (ALL) treated with chemotherapy only are at risk for neurocognitive impairment. Regions of interest were identified a priori based on glucocorticoid receptor distribution, and sex‐stratified multivariable linear regression models were used to test associations between brain MRI morphology and total number of intrathecal injections, and serum concentration of dexamethasone and methotrexate. Compared with controls, ALL survivors have persistently smaller volumes in the bilateral cerebellum (P < 0.005), hippocampal subregions (P < 0.03), temporal lobe regions (P < 0.03), frontal lobe regions (P < 0.04), and parietal lobe regions (precuneus; P < 0.002). Long‐term problems with learning may be related to residual posttreatment brain differences. 相似文献
66.
Alicia M. Blessing MD PhD Janice M. Santiago-O'Farrill MD PhD Weiqun Mao BS MD Lan Pang BS MD Jing Ning MD PhD Daewoo Pak MD PhD Lakshmi Reddy Bollu MD PhD Philip Rask BS MD LaKesla Iles BS MD Hailing Yang PhD MD Samantha Tran BS MD Ezzeddine Elmir BS MD Geoffrey Bartholomeusz MD PhD Robert Langley MD PhD Zhen Lu MD Robert C. Bast Jr MD 《Cancer》2020,126(15):3579-3592
67.
Alicia León-Castillo Ester Gilvazquez Remi Nout Vincent THBM Smit Jessica N McAlpine Melissa McConechy Stefan Kommoss Sara Y Brucker Joseph W Carlson Elisabeth Epstein Tilman T Rau Robert A Soslow Raji Ganesan Xavier Matias-Guiu Esther Oliva Beth T Harrison David N Church C Blake Gilks Tjalling Bosse 《The Journal of pathology》2020,250(3):312-322
Endometrial carcinoma (EC) molecular classification based on four molecular subclasses identified in The Cancer Genome Atlas (TCGA) has gained relevance in recent years due to its prognostic utility and potential to predict benefit from adjuvant treatment. While most ECs can be classified based on a single classifier (POLE exonuclease domain mutations – POLEmut, MMR deficiency – MMRd, p53 abnormal – p53abn), a small but clinically relevant group of tumours harbour more than one molecular classifying feature and are referred to as ‘multiple-classifier’ ECs. We aimed to describe the clinicopathological and molecular features of multiple-classifier ECs with abnormal p53 (p53abn). Within a cohort of 3518 molecularly profiled ECs, 107 (3%) tumours displayed p53abn in addition to another classifier(s), including 64 with MMRd (MMRd–p53abn), 31 with POLEmut (POLEmut–p53abn), and 12 with all three aberrations (MMRd–POLEmut–p53abn). MMRd–p53abn ECs and POLEmut–p53abn ECs were mostly grade 3 endometrioid ECs, early stage, and frequently showed morphological features characteristic of MMRd or POLEmut ECs. 18/28 (60%) MMRd–p53abn ECs and 7/15 (46.7%) POLEmut–p53abn ECs showed subclonal p53 overexpression, suggesting that TP53 mutation was a secondary event acquired during tumour progression. Hierarchical clustering of TCGA ECs by single nucleotide variant (SNV) type and somatic copy number alterations (SCNAs) revealed that MMRd–p53abn tumours mostly clustered with single-classifier MMRd tumours (20/23) rather than single-classifier p53abn tumours (3/23), while POLEmut–p53abn tumours mostly clustered with single-classifier POLEmut tumours (12/13) and seldom with single-classifier p53abn tumours (1/13) (both p ≤ 0.001, chi-squared test). Finally, the clinical outcome of patients with MMRd–p53abn and POLEmut–p53abn ECs [stage I 5-year recurrence-free survival (RFS) of 92.2% and 94.1%, respectively] was significantly different from single-classifier p53abn EC (stage I RFS 70.8%, p = 0.024 and p = 0.050, respectively). Our results support the classification of MMRd–p53abn EC as MMRd and POLEmut–p53abn EC as POLEmut. © 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland. 相似文献
68.
69.
Darren R. Feldman MD Yasser Ged MBBS Chung-Han Lee PhD Andrea Knezevic MS Ana M. Molina MD Ying-Bei Chen PhD Joshua Chaim DO Devyn T. Coskey MS Samuel Murray MS Satish K. Tickoo MD Victor E. Reuter MD Sujata Patil PhD Han Xiao MD Jahan Aghalar MD Arlyn J. Apollo MD Maria I. Carlo MD Robert J. Motzer MD Martin H. Voss MD 《Cancer》2020,126(24):5247-5255
70.